Navigation Links
Flu vaccines aimed at younger populations could break annual transmission cycle
Date:6/11/2013

CORVALLIS, Ore. The huge value of vaccinating more children and young adults for influenza is being seriously underestimated, experts say in a new report, while conventional wisdom and historic vaccine programs have concentrated on the elderly and those at higher risk of death and serious complications.

A computer modeling analysis was just published in the journal Vaccine, in work supported by the National Institutes of Health. The study suggests that children in school and young adults at work do the vast majority of flu transmission. Programs that effectively increase vaccination in those groups would have the best payoff, the research concluded.

The key point: If you don't catch the flu, you can't die from it. Breaking the cycle of transmission benefits everyone from infants to the elderly, the researchers said. And at stake are thousands of lives and billions of dollars a year.

"In most cases, the available flu vaccine could be used more effectively and save more lives by increasing the number of vaccinated children and young adults," said Jan Medlock, a co-author of the study and researcher with the Department of Biomedical Sciences in Oregon State University's College of Veterinary Medicine.

"That approach could really limit the cycle of transmission, preventing a great deal of illness while also reducing the number of deaths among high risk groups," he said. "Approaches similar to this were used in Japan several decades ago, and they accomplished just that. Our new analysis suggests we should reconsider our priorities for vaccination."

In a perfect world and in accord with recommendations from the Centers for Disease Control and Prevention, researchers agree that almost everyone over the age of six months should get the flu vaccine, unless they were allergic to the shot or had other reasons not to take it. But in the United States, only about one-third of the population actually gets a flu vaccine each year. Historic efforts have been focused on people at higher risk of death and severe disease often the elderly, and those with chronic illness, weakened immune systems, health care workers or others.

With existing patterns of vaccine usage, the problem is enormous. Seasonal influenza in the U.S. results each year in an average of 36,000 deaths, more than 200,000 hospitalizations, an $87 billion economic burden, and millions of hours of lost time at school and work not to mention feeling sick and miserable.

The flu vaccine up until 2000 was only recommended for people over 65, Medlock said, and other age groups were added in the past decade as it became clear they also were at high risk of death or complications children from age six months to five years, and adults over 50. Just recently, age was taken completely out of the equation.

"Clearly we would want people at high medical risk to get a flu vaccine as long as it is abundant," Medlock said. "But what we're losing in our current approach is the understanding that most flu is transmitted by children and young adults. They don't as often die from it, but they are the ones who spread it to everyone else."

The population and disease transmission modeling done in the new study outlines this, and concluded that a 25-100 percent reduction in deaths from flu or its complications could be achieved if current flu vaccine usage were shifted to much more heavily include children and young adults, as well as those at high risk.

One obstacle, experts say, is the historic reluctance to add even more vaccines to those already received and often mandated for school-age children.

"A simple program we could consider in our K-12 schools would be to have the school nurse, or other local professional, give every child an annual flu shot, with the parents being informed about it in advance and having the option to decline," Medlock said.

"Vaccinating children could prevent a great deal of illness and save many lives at all ages, not just the children," he said. "More aggressive educational campaigns to reach young adults would also be helpful."


'/>"/>

Contact: Jan Medlock
jan.medlock@oregonstate.edu
541-737-6874
Oregon State University
Source:Eurekalert

Related biology news :

1. Cancer vaccines self-sabotage, channel immune attack to injection site
2. Novel aptamer boosts T cell-based immune response to therapeutic vaccines
3. Designer bacteria may lead to better vaccines
4. UMMS experts seek better flu vaccines
5. MVI and Inovio partner to develop malaria vaccines using innovative vaccine delivery tech
6. Mosquito virus could lead to new vaccines and drugs
7. Early activation of immune response could lead to better vaccines
8. Compound discovered that boosts effect of vaccines against HIV and flu
9. AAPS National Biotechnology Conference to highlight innovative vaccines
10. Researchers identify Achilles heel of dengue virus, target for future vaccines
11. EWiND facility aimed at improvements in wind energy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... , Feb. 16, 2017  Genos, a ... announced that it has received Laboratory Accreditation from ... Accreditation is presented to laboratories that meet stringent ... demonstrate scientifically rigorous processes. "Genos is ... in laboratory practices. We,re honored to be receiving ...
(Date:2/14/2017)... N.C. , Feb. 14, 2017  Wake Forest ... M.D., as its new chief executive officer (CEO). Freischlag ... CEO John D. McConnell , M.D., who last ... position at the Medical Center, after leading it since ... the full scope of Wake Forest Baptist,s academic health ...
(Date:2/13/2017)... Feb. 13, 2017  RSA Conference -- RSA, a ... is designed to enhance fraud detection and investigation ... the RSA Fraud & Risk Intelligence Suite. The ... leverage additional insights from internal and external sources ... protect their customers from targeted cybercrime attacks. ...
Breaking Biology News(10 mins):
(Date:2/16/2017)... , Feb. 16, 2017  ArmaGen, Inc., a ... therapies to treat severe neurological disorders, today reported ... with AGT-181, the company,s investigational therapy for the ... as mucopolysaccharidosis type I, or MPS I). The ... (POC) study, presented today at the 13 th ...
(Date:2/16/2017)... Feb. 16, 2017   Capricor Therapeutics, Inc. ... biotechnology company developing first-in-class biological therapies for cardiac ... has elected to terminate its license agreement with ... agonists, including Cenderitide. "Our decision to ... we prioritize our efforts to advance our core ...
(Date:2/16/2017)... 16, 2017 Patient Care ... innovative telemedicine application, new and leading edge therapies ... a boom worldwide. The healthcare sector as whole ... services and new therapies for companies such as ... Cellectar Biosciences, Inc. (NASDAQ: CLRB ), ...
(Date:2/16/2017)... DIEGO , Feb. 16, 2017  Dermata ... innovative products to treat a variety of dermatological ... million Series 1a financing and entered into a ... (SVB).  Dermata intends to use the capital for ... making major advancements in the treatment of serious ...
Breaking Biology Technology: